Three children developed human herpesvirus-6 (HHV-6), variant B encephalitis after unrelated umbilical cord blood transplant, in a single center. They developed clinical manifestations of encephalitis around day 17 post transplant. Impairment of consciousness, incoherent speech, episodic focal pruritis, motor weakness, convulsions and severe hyponatremia were features at presentation. Radiological investigation of brain ranged from unremarkable to extensive white matter and meningeal lesions. Diagnosis was established by the presence of HHV-6 DNA in cerebrospinal fluid (CSF). Retrospective analyses of plasma revealed the presence of viral DNAemia prior to the onset of disease in two subjects. Treatment with ganciclovir or foscarnet was given. Two subjects did not achieve engraftment and died of other transplant-related complications on day 38 and 56 posttransplant, respectively. One subject achieved diseasefree survival for more than 1 year with a satisfactory neurological outcome. In conclusion, HHV-6 encephalitis is not uncommon among patients undergoing umbilical cord blood transplantation. It is worth conducting further studies on early diagnosis and optimal management of this potentially fatal disease. Bone Marrow Transplantation (2002) 29, 991-994.
myelosuppression associated with HHV-6 infection have also been reported.
In a recent review by Singh and Paterson, 2 significant mortality was present among 13 adult bone marrow recipients with HHV-6 encephalitis. Clinical manifestations were characterized by acute onset of encephalopathy at a median of 45 days post transplant, with 50% diagnosed within 4 weeks. Changes in CSF and radiological findings were generally lacking in these patients. The diagnosis was established by detection of HHV-6 DNA in CSF by polymerase chain reaction (PCR) in nine subjects, by both viral isolation and PCR in one subject and by histopathologic examination in one subject. Treatment with ganciclovir or phosphonoformic acid (foscarnet) seemed to improve the survival as well as to minimize residual neurologic problems upon recovery. The frequency and clinical impact of HHV-6 in hematopoietic stem cell transplantation remains uncertain. In a report on neurological complications after stem cell transplantation in children, 15.8% of 77 patients developed major neurological problems during transplant, 3 but no subject had detectable HHV-6 DNA by PCR in CSF.
Here, we report three cases of HHV-6 associated encephalitis after unrelated umbilical cord blood transplantation from 1999 to 2001, in our center. The diagnosis of encephalitis was based on the presence of a depressed or altered level of consciousness, including lethargy, extreme irritability, or a significant change in personality or behavior that persisted for у24 h, with fever, seizures, or focal neurologic findings. Laboratory findings of pleocytosis (WBC count, у5 cells/l), compatible electroencephalogram (EEG) or abnormal radiological features in the central nervous system are helpful in diagnosis. HHV-6 infection was established by detection of viral DNA by PCR as previously described. 4 Plasma specimens collected at weekly interval during transplant were retrospectively analyzed for HHV-6 DNA. All CSF specimens had undergone standard microbiological examination. In addition, the presence of herpes simplex virus 1 and 2, cytomegalovirus, human herpes virus 7, and varicella zoster virus was sought by nested PCR.
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Case reports
A 12-year-old girl received a one-antigen mismatched unrelated umbilical cord blood transplant for relapsed acute myeloid leukemia secondary to myelodysplastic syndrome in January 1999. The preparative regimen consisted of busulphan 16 mg/kg and cyclophosphamide 200 mg/kg. Infection prophylaxis included intravenous immunoglobulin, oral fluconazole, gentamicin, and vancomycin. Graft-versus-host-disease (GVHD) prophylaxis included cyclosporin 3 mg/kg/day from day Ϫ1, methotrexate 15 mg/m 2 on day 1, 10 mg/m 2 on day 3 and day 6 respectively, plus methylprednisolone from day 7 onwards. The nucleated cell dose was 4.06 ϫ 10 7 /kg. On day 4 post transplant, she had herpes zoster over her left thigh and was started on acyclovir 500 mg/m 2 , every 8 h. Concurrently, she had persisting fever without a defined focus, requiring broad-spectrum antibiotics. Subsequently, a nasopharyngeal aspirate identified parainfluenza type 2. Despite complete donor chimerism confirmed by PCR method on day 34 on peripheral blood cells, the highest attainable neutrophil count was 0.34 ϫ 10 9 /l on day 46, not fulfilling the definition of engraftment.
On day 17, she presented with an acute onset of high fever, confusion, photophobia, expressive aphasia, right VII nerve upper motor neurone palsy, right hemiplegia and double incontinence. CSF examination showed an opening pressure of 16 cm H 2 O, elevated protein of 1.9 g/l, normal glucose of 3.7 mmol/l, and pleocytosis of WBC 6/l. HHV-6 DNA variant B was detected in CSF. No viral DNA was detectable in plasma specimens collected weekly before the onset of encephalitis. Computed tomography (CT) of the brain showed a hypodense lesion in the left posterior parietal region within the first hour of presentation. A repeat CT scan after 14 h showed additional lesions in the left anterior parietal region. Magnetic resonance imaging (MRI) of the brain 4 days after the onset showed hyperintense lesions of the white matter in the left frontal and parietal lobes on T2 weighted sequence, which were not enhanced by contrast. Meningeal enhancement with contrast was evident. This radiological picture was suggestive of meningoencephalitis. Ganciclovir was started on day 18 at 5 mg/kg/dose 12h for 1 week and then switched to a daily dose. Right-sided tonic-clonic convulsions with secondary generalization were noted the next day. Her conscious level recovered gradually, but there were residual problems of expressive aphasia and being bed-ridden with spastic right hemiparesis. The follow-up CSF specimen on day 32 was negative for HHV-6 DNA. Because of the severe myelosuppression without evidence of engraftment, foscarnet was used instead from day 32 onwards. Following development of encephalitis, she had bacillus septicemia and recurrence of herpes zoster. Acute GVHD involving the skin was severe, requiring additional steroid treatment. She finally succumbed to severe pancytopenia, and candida glabrata septicemia on day 56 post transplant. Post-mortem examination was not available.
A 9-year-old boy received a two antigen mismatched unrelated umbilical cord blood transplant in August 2000 for relapsed acute lymphoblastic leukemia in fourth remission. Non-myeloablative conditioning was with total body irradiation of 9 Gy, melphalan 140 mg/m 2 and fludarabine 120 mg/m 2 . Infection prophylaxis included intravenous immunoglobulin and fluconazole. GVHD prophylaxis was cyclosporin 3 mg/kg/day from day Ϫ1 and methylprednisolone from day 7 onwards. The nucleated cell dose was 2.64 ϫ 10 7 /kg. He developed a generalized skin rash suggestive of GVHD with compatible skin biopsy findings on day 7 post transplant. Methylprednisolone (2 mg/kg/day) was given with cyclosporine for grade II GVHD. He was pyrexial without a defined infective focus. Engraftment was noted on day 19, with complete donor chimerism.
On day 17, he developed acute onset of hyponatraemia of 113 mmol/l associated with a generalized tonic-clonic convulsion. There was intense episodic pruritis with a lot of scratching over his right thigh focally while his consciousness state was stable. Three days later, his consciousness state became acutely impaired with incoherent speech. His condition deteriorated further the next day with coma, minimal response to pain, aphasia, conjugate gaze towards right side, dilated pupils of 6 mm bilaterally and sluggish response, weak extremities with just barely pointing movement of his right arm. Myoclonic spasm of his trunk was apparent. CSF examination showed RBC 460 ϫ 10 6 /l and WBC 1 ϫ 10 6 /l. No bacterial or fungal agent was identified. The only positive finding was the presence of HHV-6 DNA variant B in CSF. Radiological studies with CT and MRI were unremarkable at presentation and subsequent followup. Ganciclovir 5 mg/kg/dose 12 h was started on day 22, continued for 3 weeks and then maintained at a daily dose, 5 days weekly. Repeated CSF examination on days 42 and 104 showed disappearance of HHV-6 DNA in CSF. HHV-6 DNA, variant B was detected in plasma 1 week prior to disease onset. Due to the presence of CMV antigenemia, ganciclovir treatment was continued until day 97. He recovered from the encephalitis with gradual resolution of the episodic focal pruritis, hyponatremia and focal convulsions over the following months. He has survived now 1 year post transplant with chronic GVHD. No focal neurological deficit is present and he is independent in daily living activities.
A 6-year-old girl received a one antigen mismatched unrelated umbilical cord blood transplant in February 2001 for juvenile myelomonocytic leukemia in blastic transformation, with monosomy 7. Conditioning was with busulphan 16 mg/kg, melphalan 140 mg/m 2 , cyclophosphamide 120 mg/kg and antithymocyte globulin 90 mg/kg. Infection prophylaxis included intravenous immunoglobulin, fluconazole, and acyclovir. GVHD prophylaxis included cyclosporin and methylprednisolone as in the second case. The nucleated cell dose given was 6.25 ϫ 10 7 /kg. A skin rash suggestive of GVHD was apparent by day 5 which necessitated increasing the methylprednisolone dosage to 2 mg/kg/day. A high fever was present without a defined focus. Herpes simplex stomatitis developed on day 6. G-CSF was given to enhance neutrophil recovery by day 7. Veno-occlusive disease of liver developed by day 9 with a peak bilirubin of 298 mol/l. Engraftment was not achieved, with chimerism studies showing recipient cells only throughout.
On day 17, she started to be unusually talkative with insomnia, despite appearing tired. High fever persisted and was followed by confusion and incoherent speech after 2 days. Hyponatraemia of 124 mmol/l developed with generalized convulsions. CSF examination showed a protein of 0.17 g/l, glucose of 5 mmol/l with no pleocytosis. HHV-6 DNA variant B was detected in the CSF. The plasma specimen collected in the same week also contained HHV-6 DNA. CT of the brain at presentation was unremarkable. MRI brain performed 1 week later revealed edema of both medial temporal lobes, predominantly affecting the white matter, which was compatible with encephalitis. Repeated CTs of the brain showed multiple small hypodense lesions in both posterior parietal lobes. Myoclonic seizures were frequent, requiring multiple anticonvulsants. EEG showed a slow background with no definite epileptiform discharges. She remained confused with a lot of scratching due to pruritis over her abdomen without any skin eruption. Ganciclovir (5 mg/kg/dose 12 h) was initially given and subsequently switched to foscarnet (60 mg/kg/dose 8 h) in view of myelosuppression. However, foscarnet was associated with electrolyte disturbances involving low plasma levels of sodium, potassium, calcium, magnesium and phosphate as well as an elevated plasma creatinine. A repeat CSF study for HHV-6 remained positive 11 days from diagnosis. She finally succumbed to complications of multi-organ failure, massive gastrointestinal bleeding, and pneumonia on day 38 post transplant. Post-mortem examination was not performed.
Discussion
Our three patients were in desperate need of transplantation for their primary conditions, but had no available matched marrow donor. Umbilical cord blood provides the most readily available source of stem cells from unrelated donors with a less rigorous requirement for histocompatibility. 5 There are advantages of having a lower incidence of GVHD and similar survival results as in bone marrow transplantation. In our center, we have performed 11 umbilical cord blood transplants up to February 2001 with an increasing number in recent years. It is important to determine whether there are any complications that may occur more frequently in this type of transplant. HHV-6 infection appears to be common following allogeneic marrow transplantation. 6, 7 The immature immune capability and the lower stem cell dose of umbilical cord blood may further increase the risk of viral infection. Two of our subjects required additional steroid therapy for acute GVHD before diagnosis of encephalitis. Analyses of their plasma specimens 1 to 2 weeks prior to the onset of CNS symptoms showed detectable HHV-6 DNA. The relationship of encephalitis and viral DNAemia may be due to either hematogenous spread of the viral infection from a peripheral site to the central nervous system (CNS), or simultaneous reactivation of the latent viral infection both peripherally and in the CNS. We favor the latter as we have demonstrated that the human brain is one of the reservoirs for latent HHV-6 virus. 4 Furthermore, one subject had undetectable viral DNA in plasma when the CSF was positive. Presence of viral DNA in the CSF is informative for Bone Marrow Transplantation the diagnosis of HHV-6 encephalitis as one study demonstrated a very low prevalence of 0.9% positivity in the CSF of immunocompromised control subjects. 8 Clinical signs and symptoms of encephalitis depend on the site of brain insult. It is worth noting that the disease onset around days 17 post transplant was earlier than the median day of onset on day 45 for BMT recipients. 2 The characteristic clinical presentation included a high fever of 41°C, impaired consciousness level, speech problems, motor weakness, and convulsions. Radiological studies in our subjects suggested mostly white matter damage rather than neuronal pathology. This is in contrast to a previous case report which described predominantly grey matter involvement. 9 Hyponatremia and episodic focal pruritis were two clinical features not found in previous reports. We suspected the severe hyponatremia may be due to natriuresis in global cerebral disturbance. There was no evidence for the syndrome of inappropriate antidiuretic hormone. The two patients with severe episodic focal pruritis without skin lesions may have had an underlying insult to the ascending sensory pathway, such as a thalamic lesion. No direct evidence, however, suggested viral tropism to the sensory pathways in the brain. 10 Previous review demonstrated that treatment with ganciclovir or foscarnet in HHV-6 encephalitis improved both survival and neurological status. 2 However, prophylactic doses of ganciclovir seemed unable to prevent development of encephalitis.
11 Both ganciclovir and HHV-6 infection can be associated with myelosuppression. Two of our subjects failed to engraft, although there were other confounding factors. Foscarnet administration demands close monitoring of renal function. The only survivor among our three cases received ganciclovir throughout. In conclusion, HHV-6 encephalitis may not be uncommon among patients undergoing umbilical cord blood transplantation. It is worth conducting further studies concerning early diagnosis and optimal management of this potentially fatal disease.
